Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus
Modern Rheumatology Case Reports · 2024
DOI: 10.1093/mrcr/rxae018 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2024. Verfasst von Naoto Azuma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan. Hauptthemen laut MEDLINE: Alopecia, Lupus Erythematosus, Discoid, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits Type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE. However, there are very few reports on the effect of ANI on alopecia due to DLE. We report on a 27-year-old Japanese woman with SLE whose alopecia due to chronic DLE was refractory to topical therapy and systemic therapy with oral glucocorticoid, multiple immunosuppressants, and belimumab for ∼8 years after onset and whose alopecia improved with ANI. ANI can be considered to be an effective treatment option in lupus patients presenting with alopecia due to DLE, even in the chronic refractory stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan.
- Department of Dermatology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan.
- Hashimoto Rheumatology Clinic, Osaka, Japan.
- Division of Rheumatology and Allergy, Osaka General Medical Center, Osaka, Japan.
- Department of Rheumatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
- Department of Dermatology, Wakayama Medical University Graduate School of Medicine, Wakayama, Wakayama, Japan.
ORCID-Profile: Naoto Azuma
Zitieren
APA
Azuma, N., Natsuaki, M., Hashimoto, N., Abe, T., Ueda, S., Ohno, Y., Jinnin, M., & Matsui, K. (2024). Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxae018
Vancouver
Azuma N, Natsuaki M, Hashimoto N, Abe T, Ueda S, Ohno Y, et al. Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus. Modern Rheumatology Case Reports. 2024. doi:10.1093/mrcr/rxae018
BibTeX
@article{Azuma2024,
author = {Azuma, Naoto and Natsuaki, Masaru and Hashimoto, Naoaki and Abe, Takeo and Ueda, Suzu and Ohno, Yuko and Jinnin, Masatoshi and Matsui, Kiyoshi},
title = {Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus},
journal = {Modern Rheumatology Case Reports},
year = {2024},
doi = {10.1093/mrcr/rxae018}
}
EUVIMED